435303-34-7

Basic information

• Product Name: 5-CHLOROMETHYL-3-(4-TRIFLUOROMETHYL-PHENYL)-[1,2,4]OXADIAZOLE
• Synonyms: 1,2,4-Oxadiazole, 5-(chloromethyl)-3-[4-(trifluoromethyl)phenyl]-
• CAS NO: 435303-34-7
• Molecular Formula: C₁₀H₆ClF₃N₂O
• Molecular Weight: 262.62
• Mol File: 435303-34-7.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 314.5°Cat760mmHg
• Flash Point: 144°C
• Appearance: /
• Density: 1.418g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.496
• CAS DataBase Reference: 5-CHLOROMETHYL-3-(4-TRIFLUOROMETHYL-PHENYL)-[1,2,4]OXADIAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-CHLOROMETHYL-3-(4-TRIFLUOROMETHYL-PHENYL)-[1,2,4]OXADIAZOLE(435303-34-7)
• EPA Substance Registry System: 5-CHLOROMETHYL-3-(4-TRIFLUOROMETHYL-PHENYL)-[1,2,4]OXADIAZOLE(435303-34-7)

Safety Data

• Hazardous Substances Data: 435303-34-7(Hazardous Substances Data)

Usage

General Description

5-CHLOROMETHYL-3-(4-TRIFLUOROMETHYL-PHENYL)-[1,2,4]OXADIAZOLE is a chemical compound with a molecular formula C11H7ClF3N3O. It is a member of the oxadiazole family, which is known for its diverse range of biological activities. This specific compound is characterized by the presence of a chloromethyl group and a trifluoromethyl-phenyl group. It has potential applications in medicinal chemistry and agrochemicals due to its antibacterial and antifungal properties. Additionally, it may also be used in the development of new materials and pharmaceuticals. However, it is important to handle and use this compound with caution, as it can be toxic and harmful if not properly managed.

InChI:InChI=1/C10H6ClF3N2O/c11-5-8-15-9(16-17-8)6-1-3-7(4-2-6)10(12,13)14/h1-4H,5H2

Upstream product

• 844498-78-8 (Z)-N'-(2-chloroacetoxy)-4-(trifluoromethyl)benzimidamide 
• 79-04-9 chloroacetyl chloride 
• 184778-31-2 (Z)-N'-hydroxy-4-(trifluoromethyl)benzimidamide 
• 455-18-5 4-CF₃C₆H₄CN 
• 1401223-68-4 C₁₀H₈ClF₃N₂O₂ 
• 22179-86-8 4-(trifluoromethyl)benzamidoxime 

Downstream Products

• 883013-05-6 C₁₈H₁₀F₃N₃O₃ 
• 1219626-24-0 3-(4-fluorophenyl)-1-({3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}methyl)pyrrolidin-2-one 
• 1357616-91-1 5-(azidomethyl)-3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazole 
• 1401223-75-3 isopropyl-({3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}methyl)amine 
• 1401223-05-9 N-isopropyl-2-(4-(trifluoromethyl)phenoxy)-N-((3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)acetamide 
• 1401223-07-1 2-(4-chlorophenoxy)-N-isopropyl-N-((3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)acetamide 
• 1401223-08-2 N-isopropyl-2-phenoxy-N-((3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)acetamide 
• 1401223-09-3 N-isopropyl-2-(p-tolyloxy)-N-((3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)acetamide 

Relevant articles and documents

In vitro anti-TB properties, in silico target validation, molecular docking and dynamics studies of substituted 1,2,4-oxadiazole analogues against Mycobacterium tuberculosis

The alarming increase in multi- and extensively drug-resistant (MDR and XDR) strains of Mycobacterium tuberculosis (MTB) has triggered the scientific community to search for novel, effective, and safer therapeutics. To this end, a series of 3,5-disubstitu

Design, synthesis, and bioactivities of novel oxadiazole-substituted pyrazole oximes

A series of novel pyrazole oxime derivatives containing a substituted oxadiazole group were designed and synthesized. The bioassay results indicated that some title compounds displayed good acaricidal and insecticidal activities against Tetranychus cinnabarinus, Aphis medicaginis, Oriental armyworm, and Nilaparvata lugens. Especially, compounds 7a, 7b, and 7c had 80%, 90%, and 90% insecticidal activities against A. medicaginis at 20 μg/mL, respectively. Interestingly, some of the designed compounds displayed wonderful fungicidal activities in vivo against cucumber Pseudoperonospora cubensis. Furthermore, compounds 7a (EC50= 4.97 μg/mL) and 7h (EC50= 0.51 μg/mL) showed excellent fungicidal activity against P. cubensis comparable or better than that of the control Pyraclostrobin (EC50= 4.59 μg/mL).

Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors

Using Entinostat as a lead compound, 2-aminobenzamide and hydroxamate derivatives have been designed and synthesized. The entire target compounds were investigated for their in vitro antiproliferative activities using the MTT-based assay against five human cancer cell lines including U937, A549, NCI-H661, MDA-MB-231 and HCT116. 2-Aminobenzamide series of compounds (10a-10j) demonstrated the most significant inhibition against human acute monocytic myeloid leukemia cell line U937, but no or poor activities against two human lung cancer cell lines. Furthermore, the target compounds were screened for their inhibitory activities against HDAC 1, 2, and 8. 2-Aminobenzamide derivatives (10) manifested a higher selectivity for HDAC 1 over HDAC 2, but were not active against HDAC 8. In contrast, most hydroxamate derivatives (11) inhibit HDAC 8 with lower IC50 values than SAHA and Entinostat. Docking study with selected compounds 10f and 11a revealed that the compounds might bind tightly to the binding pockets in HDAC 2 and HDAC 8, respectively. The results suggest that they may be promising lead compounds for the development of novel anti-tumor drug potentially via inhibiting HDACs.